IL33 and colorectal carcinoma: Specifically, IL-25 has been shown to preferentially affect ILC2s and myeloid-derived suppressor cells (MDSCs) in CRC (81), while IL-33 exerts a more dominant effect on Th2 cells, Tregs, and mast cells (84, 87, 88, 91, 92, 94–96), although both can modulate eosinophils (82, 97).